Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $59.24 (market cap $77.37B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 50.6× Recursion Pharmaceuticals Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MDLZ | RXRX | |
|---|---|---|
Market Cap | $77.37B | $1.53B |
Sector | Consumer Staples | Health |
52-Week High | $70.75 | $6.79 |
52-Week Low | $51.51 | $2.84 |
Enterprise Value | $97.46B | $946.50M |
Dividend Yield | 3.32% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
